The primary mandate of Ontario Genomics’ Board of Directors is to provide strategic insight and operational governance. The Board comprises leaders from Ontario’s life science sector, including not for profit research and education institutions, pharmaceutical and biotechnology enterprises, financial entities, public policy centres, and government. Through quarterly meetings, the Board aims to fulfill Ontario Genomics’ guiding principle promoting world-class research, creating strategic genomics resources and advocating the development of a globally competitive life sciences sector. The Board members’ time and expertise are essential to our ongoing success and future direction, and we are grateful for their contributions.
- Deb Stark (Chair)
- Tom Corr (Vice-Chair)
- Stephen Cummings
- Jack Gauldie
- Diane Gosselin
- Colin Kelleher
- John Kelly
- Mark Lundie
- Alex MacKenzie
- Alison Paprica
- Benjamin Rovinski
- Alan Winter
Dr. Deb Stark is the former Deputy Minister of the Ontario Ministry of Agriculture, Food and Rural Affairs (OMAFRA). During her public service career, Deb held various senior leadership roles within OMAFRA and the Ministry of the Environment (MOE) including serving as Ontario’s first chief veterinary officer.
Deb has been a Trustee and Chair of the OPSEU Pension Trust (OPT), Chair of Hospice Wellington, and on the boards of the Veterinary Infectious Diseases Organization (VIDO), and the Canadian Veterinary Medical Association (CVMA). Deb is currently on the boards of the Canadian Agriculture Policy Institute and the Ontario Agricultural Hall of Fame Association. TOP
As President and CEO of Ontario Centres of Excellence, Tom brought more than 40 years of experience in the technology transfer, ITC, entrepreneurship, academic and venture capital sectors. He has spent most of his career as an entrepreneur and has a strong academic background. Tom is a leader in bridging the worlds of entrepreneurship, academia, government and industry.
Prior to joining OCE in 2010, Tom was CEO of the Accelerator Centre and AVP – Commercialization at the University of Waterloo. Prior to joining the University of Waterloo, he served as Director of Technology Transfer (ITC) at the University of Toronto. Before joining the University of Toronto, he spent 25 years in the private sector as an entrepreneur and as an executive with several major international technology corporations.
He holds a Doctor of Business Administration degree from Henley Management College/Brunel University in England, an MBA from the University of Toronto, the ICD.D designation from the Institute of Corporate Directors and an Advanced Post-Graduate Diploma in Management Consultancy from Henley Management College.
Tom currently serves on the boards of C-FER Technologies (Chair), OneEleven (global scale-up hub) (Chair), the Southern Ontario Smart Computing Innovation Platform (SOSCIP), the Waterloo Research and Technology Park – Accelerator Centre and OCE. TOP
Stephen is CEO and General Managing Partner of Rizolve Partners, a strategic consulting practice advising clients on: value creating strategies where the establishment of profitable, sustainable growth is the imperative; and the planning for and execution of strategic transactions and liquidity events to realize value. The firm advises CEOs and other stakeholders of both public and private concerns and has conducted numerous consulting assignments advising on acquisitions, disposals, financings, reorganizations, turnarounds, strategic positioning and growth.
Stephen’s career has foundations as a financial expert where latterly it has been focussed within the investment industry. He has held leadership positions with top quartile performing Private Equity and Venture Capital firms investing institutional capital across the globe. Prior to that he was the CFO at a global publisher. He trained and qualified as a Chartered Accountant with Deloitte in London, UK.
Stephen is a member of the Board of Directors of Ontario Genomics and is Chairman of the audit committee.
Stephen received a B. Sc. in Economics with honors from the University of Leicester in the United Kingdom. He has international credentials being a qualified CPA, CA in Ontario and is an FCA in England and Wales. He is a member of the Canadian Venture Capital Association where he has held leadership positions and Financial Executives International.
He is also a sought after speaker who has spoken in Toronto and New York on Private Equity financing, valuation and International Financial Reporting Standards. TOP
Dr. Jack Gauldie has been a member of the Ontario Genomics’ Board of Directors since September 2011.
Jack was Professor and Chair of the Department of Pathology and Molecular Medicine for 15 years (1989-2005) at McMaster University. He currently holds the title of Distinguished Emeritus University Professor. Recognized internationally for his work in defining the molecular regulation of the acute phase inflammatory response, he is a world expert in the areas of cytokine biology and the molecular regulation of inflammation and immunity. He is also the lead investigator for McMaster’s Institute for Molecular Medicine and Health. In addition to his responsibilities at McMaster, he is a Fellow of the Royal Society of Canada and the Royal College of Physicians in Edinburgh.
He earned his BSc from McMaster University and his PhD from University College London. TOP
Dr. Diane Gosselin has been passionately committed to the financing of innovative biomedical research for over 20 years. President and Chief Executive Officer of CQDM since November 2012, she joined the organization in 2008 as Vice-President, Research and Business Development where she was actively involved in the creation of CQDM. Diane has demonstrated the relevance and value of CQDM’s model by building an impressive portfolio that impact biopharmaceutical research, engaging a national network of researchers and involving senior scientists from CQDM’s pharmaceutical partners as mentors. She worked for the Fonds de solidarité FTQ (2003-2008) where she helped several companies implement their drug development strategy and contributed to a strategic initiative designed to stimulate innovation in the life sciences sector. At PROCREA BioSciences, she led the research team that developed the first worldwide non-invasive diagnostic test for endometriosis.
Diane was also involved in technological maturation, including in her role as a Board member of the Bio-Innovation Funds (2005-2008). She also served on the Board of Directors of Cardianove and Oceanova Biotechnologies (2005-2008), CQIB (2014-2016) and BIOTECanada (2014-2017). She currently sits on the Board of Montreal lnVivo, the Institut National de la Recherche Scientifique (INRS), the Canadian Institutes of Health Research (CIHR) and Ontario Genomics. She also chairs the Board of Directors of CATALIS Quebec.
Diane holds a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from Université du Québec à Montréal (UQAM) and Université Paris-Dauphine. More recently, she completed a university certification program in Corporate Governance from Université Laval. Dr. Diane Gosselin is the awardee of the 2014 UQAM’s Business School Alumni “Coup de Coeur” of the jury Award for her achievements in the life sciences sector. TOP
Colin is a serial entrepreneur specializing in angel investing in early-stage technology start-ups. His current investments are in digital agriculture, e-retailing, energy informatics and analytics, medical devices and municipal water analytics, efficiency and compliance software.
His earlier deals included investments in energy optimization technology, sustainable water technology and asset management modelling sustainability software for municipalities and utilities.
Colin was a partner and Chief Financial Officer of the Helyar Group, a leader in development cost management consulting. In 2005, he co-led the merger of the Helyar Group, the Altus Group and one other company to create one of the largest most comprehensive real estate consulting firms in North America. Subsequently, as co-lead, Colin took the new entity public on the Toronto Stock Exchange.
Colin holds a Bachelor of Science in Surveying from Trinity College and a Diploma in Construction Economics from Bolton Street College of Technology, both in Dublin, Ireland.
He is also a LEED-certified professional (Leadership in Energy and Environmental Design) and a member of the global Royal Institution of Chartered Surveyors.
Colin also graduated from the executive program at Singularity University, where he received the Singularity Prototype Challenge Award for his presentation on “Buildings of the Future”. TOP
Dr. John Kelly is the Chief Executive Officer of KeliRo Company, which supports entrepreneurs and innovation in the life sciences, agriculture, food and bioeconomy sectors in domestic and international markets. He is also Executive Vice President of Troll Bridge Creek Inc., manufacturers of KiKi Maple Sweet Water. He also was lead the Ontario Fruit & Vegetable Growers’ Association as CEO and Executive Vice President. He is formerly vice-president of the Erie Innovation and Commercialization with the Ontario Fruit & Vegetable Growers’ Association. Throughout his career, he has sought to enable innovation and diversify agriculture and food opportunities throughout Canada and elsewhere. He has a wealth of experience in the private and public sector and has held various executive and Board of Director positions with start-ups and multinational companies, including Life Sciences Ontario, Ontario South Coast Wineries and Growers Association, Ontario Hazelnut Association, Ontario Lavender Association, MaRS Landing, Land O’ Lakes, Ralston Purina, Rhone-Poulenc Canada Inc. and Aventis CropSciences Inc., as well as the Ontario Ministry of Agriculture, Food and Rural Affairs. Throughout his career, he has been focused on innovation development and implementation, actively advancing products and technologies in agriculture, food, biotechnology, pharma and the bioeconomy sectors. TOP
Dr. Mark Lundie is currently the Director of Medical Affairs, Rare Diseases, with Pfizer Canada Inc. He received a Bachelor’s of Science from the University of Waterloo ((1986) followed by a MSc from Queen’s University (1989) and a doctorate degree from Department of Pharmacology & Toxicology at Queen’s University in 1995. He joined the pharmaceutical industry with Pfizer Canada in 1997 and over the past 22 years has held a number of positions of within the Pfizer Canada Medical Division. He currently serves on the Board of Directors at Clinical Trials Ontario, the Center for Probe Development & Commercialization and Ontario Genomics. Mark has supported the development of public-private partnerships with a number of research based institutes such as the Ontario Institute of Cancer Research, the Structural Genomics Consortium, MaRS Innovation and the Center for Commercialization of Regenerative Medicine. TOP
Dr. Alex MacKenzie, an attending pediatrician at the Children’s Hospital of Eastern Ontario (CHEO) has served as the CEO and Science Director of the CHEO Research Institute as well as Vice President of Research for both CHEO and Genome Canada in addition to being founding scientist of the AeGera biotech company. Dr. MacKenzie’s laboratory has conducted translational research on the rare pediatric disorder spinal muscular atrophy over the past 25 years; in recent years has broadened its focus with its involvement in the enhance Care for Rare project to search for therapies for a larger number of rare diseases. TOP
As Vice President, Health Strategy and Partnerships, Alison is the Vector Institute’s corporate lead for health strategy, overseeing research collaborations, data partnerships and AI application projects in the health sector. Alison joined Vector with more than 20 years of management experience in the government and private and not-for-profit sectors. Prior to joining Vector, she was Director, Strategic Partnerships at the Institute for Clinical Evaluative Sciences (ICES). In that role, Alison laid the groundwork for ICES’ analytic services for the private sector, initiated their first public engagement work, and developed and expanded ICES’ partnerships with provincial, national and international health data holding organizations. From 2010 to 2013, she was the Director of the Planning, Research & Analysis Branch at the Ontario Ministry of Health & Long-Term Care, responsible for up to $60 million of annual health research investment and knowledge translation activities to ensure that research findings were applied in policy development and planning. Before she joined the Ontario Public Service, Alison worked in international pharmaceutical R&D for seven years at Eli Lilly, Astra Pharma and Genpharm Inc.
Alison holds an Honours Combined BSc in Biochemistry and Chemistry (McMaster) and a PhD in organic chemistry (Western University). She is Assistant Professor (status) at the Institute for Health Policy, Management & Evaluation at the University of Toronto where she leads courses and workshops on research leadership and management. Alison is also an Affiliate Scientist at ICES and a Senior Fellow of Massey College at the University of Toronto. TOP
Dr. Benjamin Rovinski has 28 years of investment, operational, managerial and research experience in the healthcare sector. Beni joined Lumira Ventures in 2001, where he is a Managing Director, with an investment focus on early-to late-stage private and public life sciences companies. With a proven track record of delivering results both as a senior scientist and a business executive, Beni has held several senior management positions in the biotechnology sector, including 13 years at Sanofi Pasteur (formerly Aventis Pasteur) where he was a senior scientist and director of molecular virology, with a particular focus in the areas of virology, vaccine development, recombinant protein production, and functional genomics. While at Aventis, Beni led global research and development programs in the areas of HIV/AIDS and therapeutic cancer vaccines, bringing several of them through to clinical stage.
Beni received a PhD in biochemistry from McGill University in Montréal and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. He obtained his undergraduate degree from Rice University in Houston. Beni’s current and past board roles and investment responsibilities include several private and public companies, including G1 Therapeutics (NASDAQ: GTHX); Aurinia Pharmaceuticals (NASDAQ:AUPH); Vascular Pharmaceuticals; KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Cervelo Pharmaceuticals; Health Hero Network (acquired by Bosch); Avalon Pharmaceuticals (NASDAQ: AVRX; acquired by Clinical Data, Inc.); Inovise Medical, Inc.; Protana; Signature Biosciences; and SGX Pharmaceuticals (NASDAQ: SGXP; acquired by Eli Lilly). He also serves on the board of directors of Life Sciences Ontario and the advisory board of the TO Health! industry-led initiative to promote the profile of the Toronto region’s Human Health & Sciences cluster. Beni has published over 25 scientific articles and reviews and is the recipient of 32 issued patents. TOP
Dr. Alan Winter has wide experience at senior levels in the technology sector and in government, including such roles as the President and CEO of Genome BC from 2001 to 2016, the founding President and CEO of the New Media Innovation Centre in Vancouver, the President of the ComDev Space Group in Ontario, and the President and CEO of MPR Teltech Ltd. in Vancouver. During his tenure as CEO, six companies were spun out of MPR, including PMC-Sierra and Sierra Wireless.
Prior to MPR, Alan worked for Telesat Canada, and the federal Communications Research Centre in Ottawa where he was responsible for the satellite search and rescue project (SARSAT). The international COSPAS/SARSAT system operates today and has been instrumental in saving over 35,000 lives.
Alan is currently a director of Geoscience BC, and a member of UBC’s Research and Innovation Council. He was a Trustee of the Providence Health Care Research Institute, and Chair of the BC CDC Foundation for Population and Public Health. In 2007, he received a Leadership Award from LifeSciences BC, and in 2017 he received the Don Rix Award for Lifetime Achievement. He has been a director of over 30 organizations, including Alberta Innovates Technology Futures, Blackbridge Corporation, Zedi Corporation, Discovery Capital, the BC Business Council and Oceans Network Canada. In 2017, he received the Bill Thompson Lifetime Achievement Award from the BC Technologies Industries Association (BC TIA)
On the federal side, he was Chair of the board of the Communications Research Centre (CRC), Deputy Chair of the Council of Science and Technology Advisors (CSTA), and a member of the Expert Panel on Research Performance and Science Funding, Council of Canadian Academies.
Alan is a Fellow of the Canadian Academy of Engineering (FCAE) and a Fellow of the American Association for the Advancement of Science (FAAAS). He is a Fellow of the Canadian Astronautics and Space Institute (FCASI) and received their inaugural Alouette team Award. Dr. Winter received his Ph.D. from Queen’s University at Kingston, Ontario and was recognized by the Queen’s alumni Legacy of Achievement. TOP